Research article

Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients

Elisabetta Cariani†2, Caterina P Pollara*†1, Barbara Valloncini1, Francesca Perandin1, Carlo Bonfanti1 and Nino Manca1

Address: 1Department of Experimental and Applied Medicine, Section of Microbiology, University of Brescia, and A.O. Spedali Civili, Brescia, Italy and 2Laboratorio di Patologia Clinica, Ospedale Civile S. Agostino-Esense, via Giardini 1355, 414041 Baggiovara (MO), Italy

Email: Elisabetta Cariani - ecariani@hotmail.com; Caterina P Pollara* - patriziapollara@libero.it; Barbara Valloncini - boh1975@yahoo.it; Francesca Perandin - perandin@med.unibs.it; Carlo Bonfanti - bonfanti@med.unibs.it; Nino Manca - manca@med.unibs.it

* Corresponding author †Equal contributors

Abstract

Background: Quantitative real-time PCR assays, which are more rapid and practical than pp65 antigenemia determination, are progressively becoming the preferred method for monitoring Human Cytomegalovirus (HCMV) reactivation. However, the relationship between HCMV DNA and antigenemia levels is still under investigation. The aim of this study was to analyse the relationship between HCMV DNA and pp65 antigenemia levels in order to identify clinically useful threshold values for the management of patients.

Methods: 475 consecutive samples from 156 immunosuppressed patients were tested for HCMV by pp65 antigenemia and Real-time PCR assay.

Results: 136 out of 475 consecutive samples derived from 48 patients showed evidence of HCMV infection. HCMV DNA was detected in 106 samples, pp65 antigen in 3, and both markers in 27. pp65 antigen detection was associated with higher HCMV DNA levels. The cut-off HCMV DNA level that best predicted pp65 antigenemia in this series of samples was 11,500 copies/ml, but different threshold levels could be observed for specific groups of patients. HCMV disease was observed in 5 out of 48 patients with active HCMV infection. The presence of clinical symptoms was associated with positive pp65 and with higher antigenemia levels. Higher HCMV DNA load at the onset of viral replication was correlated to the development of clinical symptoms.

Conclusion: Both pp65 antigenemia and HCMV DNA load can be useful for the prospective monitoring of immunocompromised subjects. Specific cut-off levels capable of triggering preemptive antiviral treatment should be determined in accordance to the type of test used and the characteristics of patients and prospectively validated.
cause of morbidity and mortality in immunocompromised patients. The availability of diagnostic assays for the early identification of reactivated HCMV replication has considerably improved the clinical management of immunocompromised patients, thus reducing the risk of HCMV disease and allowing pre-emptive treatment as an alternative to universal prophylaxis. The determination of pp65 antigenemia has long been the reference test for monitoring HCMV reactivation [1-4], but it requires highly skilled interpretation and processing of fresh samples [5,6]. Furthermore, the evaluation of its results may be particularly difficult in leukopenic patients [7]. More recently, the quantitation of HCMV DNA by real-time PCR methods has been proposed as a convenient alternative approach, in order to overcome the drawbacks of antigenemia assays [7-17]. The exact relationship between HCMV DNA and antigenemia levels, however, is still under investigation. Studies addressing this issue would be instrumental in finding suitable threshold levels for the clinical interpretation of HCMV DNA results.

Methods

Patients

From June 2004 to March 2005, a total of 475 consecutive blood samples were received by our Laboratory for the simultaneous determination of pp65 antigenemia and quantitative HCMV DNA in plasma. The samples came from 156 patients (56 females, 100 males, mean age 44.4 ± 18.4 years). The median number of samples per patient was 8 (range: 6–28).

Patients included 75 (48%) kidney transplant (KT) recipients, 18 (11.5%) bone marrow/stem cell transplant (BMT/HSCT) recipients (including 16 pediatric and 2 adult patients), 34 (21.8%) patients with advanced human immunodeficiency virus (HIV) infection and 29 (18.5%) patients with haematological malignancies.

Active HCMV infection was defined as the detection of HCMV antigenemia and/or DNAemia. HCMV disease was defined as the association of active infection with clinical symptoms such as: unexplained fever (> 38°C), leukopenia (white blood cells < 3.5 × 10⁹/l) and/or thrombocytopenia (platelet count < 100 × 10⁹/l), gastrointestinal symptoms, arthralgia, myalgia in KT recipients; fever, leukopenia, hepatitis, enteritis, retinitis or pneumonitis in BMT/HSCT recipients; colitis, oesophagitis, hepatitis, encephalitis or retinitis in patients with advanced HIV infection; fever and neutropenia (≤ 500 neutrophils/ul) in haematological patients.

No antiviral prophylaxis was given to KT recipients, that received steroids (methylprednisolone 500 mg IV) before transplantation. In addition the patients received either an anticalcineurin agent or sirolimus. Intravenous ganciclovir or valganciclovir was administered when 50 or more pp65-antigen positive cells were detected. BMT/HSCT recipients underwent standard prophylaxis for bacterial and fungal infections, and received acyclovir 5 mg/kg body weight. Prophylaxis for HCMV infection was not administered. Intravenous ganciclovir (5 mg/kg of body weight every 12 h for 14 days, adjusted to renal function) was started when > 1 pp65-positive cells/200,000 PMNL were detected, or after two consecutive HCMV DNA-positive samples. The same criteria were used for pre-emptive treatment of haematological patients. Patients with advanced HIV infection had CD4 cell count < 100 × 10⁶/l and positive HCMV serology. They received antiretroviral therapy but no HCMV prophylaxis. Antiviral therapy was started when > 100 pp65-antigen positive cells/200,000 PMNL and/or HCMV DNA load > 100,000 copies/ml was detected.

The donor/recipient serological status was determined before transplantation by a commercially available enzyme-linked immunosorbent assay (BEIA CMV IgG Quant, Bouty, Italy) according to the manufacturer's instructions.

All transplanted patients were monitored for the presence of active HCMV replication for 6 months after transplantation. Determination of HCMV DNA load and of pp65 antigenemia was carried out once (in the absence of HCMV reactivation) or twice a week (during HCMV active replication) until disappearance of antigenemia and/or DNAemia; subsequently, HCMV replication was monitored monthly. HIV-infected and haematological patients were monitored monthly during routine clinical controls. In the presence of clinical signs or symptoms suggestive of HCMV disease monitoring was carried out once a week.

HCMV pp65 antigenemia assay

Twin blood samples were collected in citrate-anticoagulated tubes for pp65 antigenemia and quantitative real-time PCR. One sample was processed for antigenemia within 4 hours, and the other was stored for quantitative plasma DNA determination. The determination of HCMV antigenemia was carried out using a HCMV Bright Turbo kit (Lagitre U.S.A.) according to the manufacturer's instructions. The number of pp65-positive polymorphonuclear leukocytes (PMNL) was determined after staining with specific fluorescein isothiocyanate-labelled monoclonal antibodies, with results expressed as the number of positive cells per 200,000 PMNL.

HCMV DNA quantitation

DNA extraction from plasma (200 µl) was performed using a QiaAmp DNA Mini Kit (Qiagen, Germany) according to the manufacturer's instructions. HCMV DNA quantitation was carried out by a commercially available
real-time PCR test: TaqMan Q-CMV Real Time System (Cepheid, Nanogen Advanced Diagnostic, USA). This test is based on the simultaneous amplification of the HCMV MIEA (Major Immediate Early Antigen) gene (HCMV UL123-exon 4) and of internal control human beta globin gene DNA, that was added to each sample at a known concentration during specimen processing to monitor DNA extraction and recovery, amplification and detection. Specific TaqMan probes labelled with different reporter molecules (FAM/MGB-NFQ and VIC/MGB-NFQ) were used for target quantitation by interpolation of fluorescent signal intensity with a standard curve derived from the amplification of serially diluted HCMV DNA standards.

The assay was performed according to the manufacturer’s recommendations. Briefly, DNA (5 µl) was added to the PCR mixture containing 5 mM MgCl2, 0.5 µM of each primer and probe and 0.025 U of uracyl-N-glycosylase (UNG). The PCR conditions were: decontamination at 50°C for 2 minutes, initial denaturation at 95°C for 10 minutes followed by 45 cycles of 15 sec at 95°C and 1 minute at 65°C. A plasmid containing UL123 gene diluted to give a standard curve of 2 log10 to 5 log10 copies per reaction was used as a standard for quantification. PCR reactions were performed using an ABI Prism 7300 Sequence Detection System (PE Applied Biosystems). The linear interval of the assay’s analytical sensitivity as assessed by the manufacturer was between 316 and 12.5 × 10^6 HCMV DNA copies/ml of plasma.

Cost analysis
The costs of the assays were measured in terms of requirements for time, reagents or kits, and labour.

Statistical analysis
HCMV DNA levels were compared by Mann-Whitney U test. The correlation between HCMV DNA and pp65 antigenemia was analysed using the Spearman correlation coefficient.

The differences between groups were analysed using the Chi-square test or the Fisher's exact test, as appropriate. A P value of < 0.05 was considered as statistically significant.

Receiver-operating characteristic (ROC) curve analysis was carried out on the MedCalc statistical software, version 7.5.00.

Results
Analytical performance of the real-time PCR assay
To analyse the precision of the real-time PCR assay, inter- and intra-assay variations were calculated by testing three plasma pools containing samples with low (500–5,000 HCMV DNA copies/ml), intermediate (10,000–70,000 HCMV DNA copies/ml) and high (70,000–120,000 HCMV DNA copies/ml) viral load value. Intra-assay variation was evaluated by quantifying HCMV DNA load in triplicate for each plasma pool while inter-assay variation was calculated by analysing each plasma pool in four different assays.

The mean DNA loads (copies/ml) detected in the low, intermediate and high titre plasma pools, and intra-/inter-assay percent coefficients of variation (CV%) are shown in Table 1.

Correlation between pp65 and HCMV DNA load
Of the 475 samples analysed, 339 (71.3%) were negative for both HCMV DNA and pp65 antigenemia. The remaining 136 samples, taken from 48 patients (20 females, 28 males, mean age 42.3 ± 17.8 years), were positive for HCMV DNA (106 samples, 78.7%), pp65 antigenemia (3 samples, 2.2%), or both (27 samples, 19.1%). HCMV assay results were discordant for 109 out of 475 samples (22.95%). Altogether, 51 episodes of active HCMV replication (defined by positive results of HCMV DNA and/or pp65 in at least two consecutive samples) were detected.

The overall pp65 antigenemia values were statistically correlated to HCMV DNA levels (p < 0.0001). All samples containing detectable pp65 antigen had significantly higher HCMV DNA levels (median: 59,230 copies/ml; range: 0–1.47 × 10^6) compared to pp65-negative samples (median: 2,830 copies/ml; range: 0–1.58 × 10^6) (p < 0.0001) (Figure 1).

Table 1: Reproducibility of real-time PCR with low-, intermediate-, and high-titre plasma pools.

| PLASMA POOLS | PRECISION | Low-titre | Intermediate-titre | High-titre |
|--------------|-----------|-----------|--------------------|------------|
| Mean value (copies/ml) | CV% | Mean value (copies/ml) | CV% | Mean value (copies/ml) | CV% |
| Intra-assay | 3,162 | 27.8 | 50,119 | 23.5 | 100,000 | 21.2 |
| Inter-assay | 3,981 | 28.8 | 63,096 | 23.3 | 107,000 | 26.7 |
Significant differences were observed among median HCMV DNA levels in the different risk groups (Table 2). Samples from KT recipients contained significantly higher HCMV DNA levels compared to those derived from BMT/HSCT recipients (p < 0.0001), HIV-infected (p = 0.0056), and haematological patients (p = 0.0001).

The cut-off HCMV DNA level that best predicted positive pp65 antigenemia in the entire study population was identified by ROC curve analysis as 11,500 copies/ml (area under curve: 0.867; sensitivity: 88.9%; specificity: 79.2%). When the analysis was focused on single groups of patients, different threshold values between pp65-positive and -negative samples were found in KT recipients (cut-off: 24,000 copies/ml; area under curve: 0.888; sensitivity: 100%; specificity: 78%) compared to BM/HSCT recipients (cut-off: 9,960 copies/ml; area under curve: 0.605; sensitivity: 58.3%; specificity: 94.3%). The low number of pp65-positive samples in the remaining groups of patients (Table 2) did not allow for statistical analysis. To better define the cost-effectiveness of pp65 and of HCMV DNA in predicting HCMV reactivation and disease, we considered the cost and technical required time of each determination. The real-time PCR assay for HCMV DNA quantitation takes 180 minutes (DNA extraction included) with a total time for the production a results of five hours, whereas the pp65 antigenemia procedure requires 300 minutes for single test and a time for results of ten hours. The cost per sample with antigenemia and real-time PCR tests are Euro 10.31 and Euro 35.09, respectively.

**Clinical utility of pp65 and HCMV DNA load**

HCMV disease occurred rarely as symptomatic infection was observed in 5 of 48 patients with active HCMV replication (10.4%). HCMV DNA was detected in all 48 patients whereas pp65 was detected in 11, including 5 with symptomatic infection (p < 0.001).

Among KT recipients (24 patients, 22 of which donor [D] positive [+] /recipient [R] +, 1 D+/R negative [-], 1 D-/R-) only one patient (D+/R-; 4.17%) developed symptomatic infection (fever and leukopenia) 44 days after transplantation. In this patient the diagnosis of HCMV infection was based on the simultaneous detection of pp65 and HCMV DNA. In the remaining 23 asymptomatic KT recipients, diagnosis of HCMV reactivation was made due to the detection of HCMV DNA with (4 cases) or without (20 cases) pp65.

HCMV disease symptoms, including fever, leukopenia, increased aminotransferase levels, gastritis and pneumonitis, were observed in 4 (66.6%) out of 8 BMT/HSCT D+/R+ recipients during the first two months [range: 20–59 days] after transplantation. HCMV DNA preceded the onset of symptoms and pp65 detection in 3 of 4 cases, whereas pp65 and HCMV DNA appeared simultaneously in the last patient. The remaining 4 asymptomatic BMT/HSCT recipients only showed low-level HCMV DNA in the absence of pp65. In the remaining patients asymptomatic.

\[ \text{Figure 1} \]

HCMV DNA levels in pp65-positive and -negative samples. The horizontal lines represent median HCMV DNA values in the two groups of samples.

---

**Table 2: Detection of HCMV DNA and pp65 in different groups of patients**

| Groups          | n. positive patients (samples) | Median HCMV DNA copies/ml (range) |
|-----------------|--------------------------------|----------------------------------|
|                 | HCMV DNA | pp65                             |
| KT recipients   | 24 (66)  | 5 (16)                           | 17,020 (438-1.58 × 10⁶) |
| BMT/HSCT recipients | 8 (44)  | 4 (12)                           | 2,480 (316-3.1 × 10⁶) |
| HIV             | 10 (14)  | 2 (2)                            | 2,615 (240-2 × 10⁵) |
| HM              | 6 (9)    | 0                                | 1,100 (316-2.7 × 10⁵) |
| Total           | 48 (133) | 11 (30)                          | 5,841 (240-1.58 × 10⁶) |

KT: kidney transplant; BMT/HSCT: bone marrow/stem cell transplant; HIV: patients with advanced human immunodeficiency virus infection; HM: patients with haematological malignancies.
matic HCMV reactivation was diagnosed by the detection of HCMV DNA alone (15 cases) or simultaneously with pp65 (1 case). Altogether, HCMV DNA appeared before antigenemia in 3 out of 5 patients developing symptoms and in none of 6 pp65-positive patients without symptoms of HCMV disease.

In symptomatic patients 29.1% of samples were positive for pp65 compared to 11.8% in asymptomatic patients (p < 0.001) (Table 3). Moreover, symptomatic infection was accompanied by higher pp65 levels (median: 30 cells/200,000 PMNL, range 3–100, vs median: 11.5 cells/200,000 PMNL, range 1–85, in asymptomatic patients; p = 0.029). ROC curve analysis showed that the best cut-off pp65 value predictive of symptomatic infection was 13 cells/200,000 PMNL (area under curve: 0.734; sensitivity: 81.2%, specificity: 57.1%). By contrast, median HCMV DNA levels did not differ significantly between symptomatic (7,500 copies/ml) and asymptomatic patients (4,580 copies/ml).

Median HCMV DNA level in the first positive sample was 22,400 copies/ml (range: 1830–520,000) in the 5 symptomatic patients, and 2677 copies/ml (range: 280–413,820) in the 43 asymptomatic patients (p = 0.029). By contrast, the number of pp65 positive cells in the first positive sample did not differ significantly between symptomatic and asymptomatic patients (30 cells/200,000 PMNL, range 3–80, vs. 11 cells/200,000 PMNL, range 3–85; p = 0.17). A HCMV DNA load > 7880 copies/ml at first detection could predict the onset of symptoms with 80% sensitivity and 79.1% specificity (area under curve: 0.800).

HCMV infection responded to ganciclovir in all patients. The clinical monitoring of symptomatic patients during treatment revealed that pp65 became undetectable after 8–17 days (median: 12.5 days), whereas HCMV DNA decreased more slowly disappearing 7–105 days (median: 41 days) after the beginning of treatment. Similar results were observed among patients without clinical symptoms: pp65 (detected in 6) disappeared after 7–20 days (median: 14 days), whereas HCMV DNA persisted for 3–51 days (median: 33 days).

Discussion

HCMV pp65 antigenemia is known to be clinically useful for the management of HCMV reactivation in immunocompromised patients [1-4]. Cut-off antigenemia levels have been proposed as an option to trigger treatment in different patient populations [18-20], which would reduce the incidence of HCMV-related disease.

Real-time PCR methods for HCMV DNA quantitation could offer a convenient alternative for monitoring HCMV replication which is less influenced by the quality of sample and more suited to standardization and automation, compared to antigen detection tests. In addition, real-time PCR requires a small volume of plasma (200 µl) compared to 3–5 ml of whole blood required for antigenemia, and can be done on neutropenic patients. Finally, despite being considerably cheaper, pp65 requires longer technical labour and longer time for the production of a result and the processing of fresh samples.

Although several studies have already addressed this issue [9,13,14,16,19-23], the correlation between antigenemia results and real-time PCR, as well as the clinical significance of both assays, requires further evaluation. When we analysed a series of consecutive samples referred to our laboratory, the sensitivity of the real-time PCR-based test in detecting HCMV infection was considerably higher than that of pp65 determination, although pp65 was detected in 3 samples with no evidence of HCMV DNA. These samples were consecutively derived from a single HSCT recipient after a symptomatic episode of HCMV reactivation with simultaneous detection of pp65 and DNA (data not shown).

Discrepancies between the two HCMV markers may be linked to the distinct viral components analysed here (protein vs. genome), the different districts considered (PMNL vs. plasma), the sensitivity threshold of the tests. The observation of pp65-positive, HCMV DNA-negative samples could be due to pp65 transfer from endothelial cells to adhering PMNL, in the absence of viral replication [13,24]. A significant correlation between pp65 antigenemia and HCMV DNA levels was demonstrated using a non-parametric test, despite the wide dispersion of HCMV DNA levels.

Table 3: Comparison of HCMV DNA and pp65 detection in 55 samples obtained from 5 symptomatic (with HCMV disease) and 119 samples from 43 asymptomatic (without HCMV disease) patients with active virus replication.

| VIRAL MARKER          | TOTAL SAMPLES |
|-----------------------|---------------|
|                       | WITH HCMV DISEASE | WITHOUT HCMV DISEASE |
| HCMV-DNA positive     | 43             | 90              | 133              |
| HCMV-DNA negative     | 12             | 29              | 41               |
| HCMV-pp65 antigen positive | 16           | 14              | 30               |
| HCMV-pp65 antigen negative | 39            | 105             | 144              |
DNA levels observed, in agreement with previous studies [13,14,20].

Prospective laboratory monitoring of patients allows for the timely adoption of therapeutic measures, thus reducing both the incidence and severity of HCMV disease in immunocompromised patients. Some studies describe an earlier rise in HCMV DNA levels, compared to antigenemia, in prospectively monitored patients [11,14,17], while the opposite observation was reported by others [24,25]. In the present study both antigenemia and DNA were first detected together in 8 out of 11 pp65-positive cases. Furthermore, antigenemia disappeared earlier compared to HCMV DNA both in symptomatic and in asymptomatic patients, consistent with other reports [25].

HCMV DNA levels were compared between samples with/without evidence of pp65-positive cells, considering pp65 antigenemia > 0 as the lowest possible cut-off level for the prediction of active HCMV infection. Significantly higher HCMV DNA levels were associated with the presence of pp65 antigenemia, while the threshold HCMV DNA value for optimal discrimination of pp65-positive or -negative samples differed according to the risk group. This observation suggests that the level of immune suppression can influence the relationship between HCMV DNA replication and symptomatic HCMV disease. Accordingly, different cut-off HCMV DNA values for risk of disease were detected in solid organ and stem-cell transplant recipients [14]. The identification of discrepant threshold levels also suggests that the optimum cut-off value should be assessed specifically for each centre and assay [19].

HCMV disease was observed in only 5 transplant recipients (10.4% of patients showing HCMV reactivation), who developed symptomatic infection shortly after kidney transplantation (1 patient) or BM/HSC transplantation (4 pediatric patients). The detection of pp65 was associated with symptomatic infection, and significantly higher pp65 levels were observed in symptomatic patients. A cut-off antigenemia level of 13 positive cells/200,000 PMNL, comparable to previous results [21], allowed the best discrimination between symptomatic and asymptomatic patients. By contrast, both HCMV DNA detection and the circulating DNA load could not distinguish between symptomatic and asymptomatic patients. However, at onset of reactivation, HCMV DNA load was significantly higher in patients that developed disease, with best discrimination at about 8,000 copies/mL, a higher value compared to a previous result (2,000 copies/mL) obtained with a commercial quantitative PCR [21].

**Conclusion**

In this study pp65 antigenemia, despite lower sensitivity for the diagnosis of HCMV active infection compared to HCMV DNA load, showed better qualitative and quantitative correlation with the presence of symptoms. Only at onset of active replication was the DNA load able to discriminate patients at risk of developing HCMV disease. On technical grounds however pp65 antigenemia, although less expensive, is often difficult to perform in leukopenic samples and suffers from major pitfalls such as labor-intensive manual procedure, requirement for immediate sample processing, subjective interpretation of results. Thus both tests can be useful for the prospective monitoring of immunocompromised subjects. Clinically relevant cut-off levels should be identified for specific groups of patients and assays, and prospectively validated for their predictive value over the development of clinical symptoms of infection.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

EC and CPP designed the study, collected clinical data, analyzed the results, and wrote the manuscript; BV carried out experimental work and collected laboratory data; FP and CB contributed to data collection and draft of the manuscript; and NM revised the manuscript. All authors read and accepted the final version of the manuscript.

**Acknowledgements**

The authors wish to thank Patrizia Beccalossi and Sergio Bergomi for technical assistance.

**References**

1. Van den Berg AP, Van der Bij W, Van Son J, Anema J, Van der Giessen M, Schirm J, Tegress AM, The TH: *Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation – a report of 130 consecutive patients*. Transplantation 1989, 48:991-995.

2. Mazzulli T, Rubin RH, Ferraro MJ, D’Aquila RT, Doveikis SA, Smith BR, The TH, Hirsch MS: *Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS*. J Clin Microbiol 1993, 31:2824-2827.

3. Kusne S, Grossi P, Irish W, St. George K, Rinaldo C, Rakele J, Fung J: *Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients*. Transplantation 1999, 68:1125-1131.

4. Sia IG, Patel R: *New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients*. Clin Microbiol Rev 2000, 13:83-121.

5. Boeckh M, Woogerd PM, Steevers-Ayers T, Ray CG, Bowden RA: *Factors influencing detection of quantitative cytomegalovirus antigenemia*. J Clin Microbiol 1994, 32:832-834.

6. Schafer P, Teuscher W, Gutensohn K, Laufs R: *Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay*. J Clin Microbiol 1997, 35:741-744.

7. Limaye AP, Huang ML, Leisenring L, Stensland L, Corey L, Boeckh M: *Cytomegalovirus (CMV) DNA load in plasma for the diagno-
sis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001, 183:377-382.
8. Tsuchida N, Kimura H, Iida K, Saito Y, Tsuge I, Yoshimi A, Matsumura T, Morishita T: Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J Med Virol 2000, 60:455-462.
9. Guiver M, Fox A, Mutton K, Mogulkoc N, Egan J: Evaluation of CMV viral load using TaqmanTM CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant patients. Transplantation 2001, 71:1609-1615.
10. Kearns AM, Guiver M, James V, King J: Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus. J Virol Methods 2001, 95:121-131.

11. Lehto VM, Osachée M, Delarue R, Sauget A-S, Blanche S, Buzy A, Rouzious C: Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 2003, 41:2040-2046.
12. Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang Y-W: Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 2003, 41:187-191.
13. Mengelle C, Pasquier C, Rostaing L, Sandres-Sauné K, Puel J, Berges L, Rigby L, Bouquies C, Isopet J: Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Virol 2003, 69:225-231.
14. Kalpoe SS, Kroes ACM, de Jang MD, Schinkel J, de Brouwer CS, Beersma MFC, Class ECJ: Validation of clinical application of cytomegalovirus DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004, 42:1498-1504.
15. Piiparinen H, Hockerstedt K, Lappalainen M, Suni J, Hautenschlager I: Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002, 40:2945-2952.
16. Piiparinen H, Hockerstedt K, Grönhagen-Riska C, Hautenschlager I: Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and Taq Man assay, and pp65 antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004, 30:258-266.
17. Schvorer E, Henriot S, Zachary P, Fritsch S, Meyer N, Caillard S, Lioure B, Stoll-Keller F: Monitoring low cytomegalovirus viremia in transplanted patients by a real-time PCR on plasma. J Med Virol 2005, 76:76-81.
18. Kim CK, Song JH, Pekk KR, Oh W, Huh W, Kim YG, Kim SJ, Joh JW, Lee NY, Park CG, Hwang ES, Cha CY, Oh HJ: Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Transplantation 2003, 75:2151-2155.
19. Seehofer D, Meisel H, Reyes N, Stein A, Langrehr JM, Settmacher U, Neuhaus P: Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. J Med Virol 2004, 75:121-131.
20. Nitsche A, Oswald O, Steuer N, Schetelig J, Radonic A, Thulke S, Siegert W: Quantitative real-time PCR compared with pp65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: which test better predicts CMV disease development? Clin Chem 2003, 49:1683-1685.
21. Amarim ML, Cabada JM, Seca R, Mendes AC, Castro AP, Amarim JM: CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays. BMC Infect Dis 2001, 1:12.
22. von Muller L, Hinz J, Bommer M, Hampf W, Kluwick S, Wiedmann M, Bunjes D, Mertens T: CMV monitoring using blood cells and plasma: a comparison of analysis of apples with oranges? Bone Marrow Transplant 2007, 39:353-357.
23. May G, Kuhn JE, Eing BR: Comparison of two commercially available pp65 antigenemia tests and COBAS Amplicor CMV Monitor for early detection and quantification of episodes of human CMV-viremia in transplant recipients. Interziology 2004, 90:261-265.
24. Gerna G, Percivalle E, Baldanti F, Sossani S, Lanzarini P, Genini E, Lillier D, Revello MG: Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 2000, 74:5629-5638.
25. Gentile G, Picardi A, Capobianchi A, Spagnoli A, Cudillo L, Dentamaro T, Tendas A, Cupelli L, Ciotti M, Volpi A, Amadori S, Martinò P, De Fabritis P: A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis 2006, 6:167.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/7/138/prepub